Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline.
Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline.
复制标题
DOI：
10.1002/mds.28838
复制
发表时间：
2022-03
影响因子：
8.6
通讯作者：
Vaillancourt, David E.
中科院分区：
文献类型：
--
作者：
Arpin, David J.;Mitchell, Trina;Archer, Derek B.;Burciu, Roxana G.;Chu, Winston T.;Gao, Hanzhi;Guttuso, Thomas;Hess, Christopher W.;Lai, Song;Malaty, Irene A.;McFarland, Nikolaus R.;Pasternak, Ofer;Price, Catherine C.;Shukla, Aparna Wagle;Wu, Samuel S.;Okun, Michael S.;Vaillancourt, David E.
雷沙吉兰作为帕金森氏病(PD)潜在的疾病修饰疗法已受到关注。雷沙吉兰是否具有改善疾病的作用仍存在疑问。这项研究的主要目的是确定雷沙吉兰在一年以上的帕金森病患者中是否具有改善疾病的效果。其次，我们评估了两种扩散磁共振成像脉冲序列，以确定测量疾病进展的最佳序列。这项前瞻性、随机、双盲、安慰剂对照试验评估了在12个月内每天服用1毫克雷沙吉兰治疗早期帕金森病的效果。主要结果是用两个扩散磁共振成像脉冲序列测量了黑质后部(PSN)自由水积累的1年变化，一个序列的重复时间(Tr)为2500 ms(短tr；n=90)，另一个序列的重复时间(Tr)为6400 ms(长tr；n=75)。二次临床结果也进行了评估。两组间PSN自由水积累量的绝对变化差异无统计学意义(短TR：P=0.346；长TR：P=0.228)。两组之间的任何次要临床结果均未发现显著差异。长tr而不是短tr的数据显示，PSN自由水在一年中显著增加(P=0.025)。运动障碍协会帕金森病统一评定量表第三部分运动功能评分在1年内显著增加(P=0.009)，运动障碍协会帕金森病统一评定量表第三部分运动功能1年变化(P=0.004)和运动迟缓评分1年变化(P=0.044)相关。我们没有发现1毫克/天的雷沙吉兰在一年以上的帕金森病中有改善疾病的效果的证据。我们发现PSN游离水在1年内增加，基线游离水与临床运动进展相关，证明了弥散成像参数对检测和预测PD进展的重要性。
Rasagiline has received attention as a potential disease-modifying therapy for Parkinson’s disease (PD). Whether rasagiline is disease modifying remains in question. The main objective of this study was to determine whether rasagiline has disease-modifying effects in PD over 1 year. Secondarily we evaluated two diffusion magnetic resonance imaging pulse sequences to determine the best sequence to measure disease progression. This prospective, randomized, double-blind, placebo-controlled trial assessed the effects of rasagiline administered at 1 mg/day over 12 months in early-stage PD. The primary outcome was 1-year change in free-water accumulation in posterior substantia nigra (pSN) measured using two diffusion magnetic resonance imaging pulse sequences, one with a repetition time (TR) of 2500 ms (short TR; n = 90) and one with a TR of 6400 ms (long TR; n = 75). Secondary clinical outcomes also were assessed. Absolute change in pSN free-water accumulation was not significantly different between groups (short TR: P = 0.346; long TR: P = 0.228). No significant differences were found in any secondary clinical outcomes between groups. Long TR, but not short TR, data show pSN free-water increased significantly over 1 year (P = 0.025). Movement Disorder Society Unified Parkinson’s Disease Rating Scale testing of motor function, Part III increased significantly over 1 year (P = 0.009), and baseline free-water in the pSN correlated with the 1-year change in Movement Disorder Society Unified Parkinson’s Disease Rating Scale testing of motor function, Part III (P = 0.004) and 1-year change in bradykinesia score (P = 0.044). We found no evidence that 1 mg/day rasagiline has a disease-modifying effect in PD over 1 year. We found pSN free-water increased over 1 year, and baseline free-water relates to clinical motor progression, demonstrating the importance of diffusion imaging parameters for detecting and predicting PD progression.
登录
查看更多内容
DOI：
10.1093/brain/awx146
发表时间：
2017-08-01
期刊：
Brain : a journal of neurology
影响因子：
--
作者：
Burciu RG;Ofori E;Archer DB;Wu SS;Pasternak O;McFarland NR;Okun MS;Vaillancourt DE
通讯作者：
Vaillancourt DE
影响因子：
5
作者：
Abu-Raya, S;Tabakman, R;Lazarovici, P
通讯作者：
Lazarovici, P
帕金森氏病的底底尼格拉无水纵向增加。
DOI：
10.3174/ajnr.a5545
发表时间：
2018-03
期刊：
AJNR. American journal of neuroradiology
影响因子：
--
作者：
Guttuso T Jr;Bergsland N;Hagemeier J;Lichter DG;Pasternak O;Zivadinov R
通讯作者：
Zivadinov R
影响因子：
3.7
作者：
Shimony, Joshua S.;Rutlin, Jerrel;Perlmutter, Joel S.
通讯作者：
Perlmutter, Joel S.
影响因子：
3.3
作者：
Pasternak, Ofer;Sochen, Nir;Assaf, Yaniv
通讯作者：
Assaf, Yaniv